{"id":"NCT01114828","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema","officialTitle":"A Multi-center, Double-blind, Parallel-arm Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2011-10","completion":"2011-12","firstPosted":"2010-05-03","resultsPosted":"2014-01-31","lastUpdate":"2014-03-04"},"enrollment":40,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cirrhosis"],"interventions":[{"type":"DRUG","name":"OPC-41061","otherNames":[]},{"type":"DRUG","name":"OPC-41061","otherNames":[]}],"arms":[{"label":"3.75 mg","type":"EXPERIMENTAL"},{"label":"7.5 mg","type":"EXPERIMENTAL"}],"summary":"OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics, efficacy, and safety will be investigated.","primaryOutcome":{"measure":"Body Weight","timeFrame":"Bseline, Day 7 or at the discontined of treatment","effectByArm":[{"arm":"OPC-41061 3.75 mg","deltaMin":-1.14,"sd":0.86},{"arm":"OPC-41061 7.5 mg","deltaMin":-1.37,"sd":2.05}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":19},"commonTop":["Thirst","Skin Exfoliation","Nausea","Pyrexia","Blood Pressure Decreased"]}}